Finland· FI-REL-REL16121

Roferon-A

A interferon alfa-2a product containing interferon alfa 2a, registered in Finland by Roche Oy. The same ATC class is registered in 4 of our 19 countries.

ATC L03AB04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedRoferon-AATCL03AB04REGISTER NO.FI-REL-REL16121PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Interferon alfa-2a is registered in 4 of 19 countries.

Countries holding a registration under ATC L03AB04 (interferon alfa-2a), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 3 of them publish a price we can compare per daily dose

Interferon alfa-2a · ATC L03AB04

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Interferon alfa 2a
Manufacturer
Roche Oy
Country
Finland (FI)
ATC code
L03AB04
ATC class
Interferon alfa-2a
Defined daily dose
2 MIO, E
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

235 interactions on record for interferon alfa-2a.

Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Interferon alfa-2a · interactions on record

235 records

  • 36 severe
  • 197 moderate
  • 2 minor

Most severe, free to view

  • EltrombopagB02BX05severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d8a7e894-d2ee-4074-a0bb-66a1c85c80b8
GET /v1/drugs/d8a7e894-d2ee-4074-a0bb-66a1c85c80b8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "2",
  "form": "injektioneste, liuos, esitäytetty ruisku",
  "route": null,
  "ddd_unit": "MU",
  "strength": "6 milj.IU/0.5 ml",
  "atc_label": "interferoni alfa-2a",
  "ma_number": "16836",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL16121",
  "authorised_at": "2001-12-17"
}

See everything about interferon alfa-2a.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.